Isomorphic Labs Pentest banked €1930M ($2.1B) in a Series B funding round led by Thrive Capital. The financing also includes participation from GV and parent company Alphabet.
The London-based company operates as a specialist biotech firm focusing on AI drug discovery. Spun out from Google DeepMind, it uses computational models to predict molecular interactions and identify potential new medications, significantly shortening the traditional research and development timeline for complex diseases.
This massive injection follows the company’s transition from a research-heavy entity into a commercial partner for global pharmaceutical laboratories. The capital will support the expansion of its engineering and biological science teams in the UK as it moves further into the drug design phase.
The scale of this round highlights the intense concentration of capital within the European AI sector, particularly where proprietary data and deep-tech heritage intersect with the life sciences market.
Originally reported by Tech Funding News.